Autoantibodies neutralizing type I interferons in patients with life-threatening COVID-19 pneumonia: a meta-analysis from 2020–2026
Abstract
Autoantibodies neutralizing type I IFNs (AAN–IFN-I) have been found in significant proportions of cases of severe, critical, and fatal COVID-19 pneumonia. We performed a systematic review of 54 studies reporting auto-Abs against type I IFNs and a meta-analysis of 20 studies reporting auto- Abs neutralizing type I IFNs published between 2020 and 2026. The meta-analysis included data for 11,380 SARS-CoV-2-infected individuals from Europe, North America, South America, Asia, the Middle East, North Africa and international multicenter cohorts, including 7,814 with severe or critical disease (69%). The pooled prevalence of AAN–IFN-I was estimated at 7.9% (95% CI, 6.0–10.4). Disease severity was strongly associated with AAN–IFN-I prevalence (OR, 11.7; 95% CI, 7.6–17.9; P =5×10⁻²⁹). The pooled prevalence of AAN-IFN-I reached 11.4% (95% CI, 10.2– 12.7%) in patients with severe or critical COVID-19 and 15.3% (95% CI, 12.1–19.2%) in those who died. The prevalence of AAN–IFN-I increased with age in patients with severe, critical, or fatal COVID-19. AAN-IFN-I probably accounted for about 1.1 million of the 7.1 million deaths from COVID-19. AAN-IFN-I are strong, common, global determinants of life-threatening COVID-19 pneumonia.
Related
- Auto-antibodies neutralizing type I interferons in ~10% of Moroccan patients with life-threatening COVID-19
- Autoantibodies Against Type I Interferons and Death from H7N7 Avian Flu
- High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies
- Type I IFN autoantibodies in three of seven Europeans with life-threatening Usutu virus infection.
- Treating More Than One Tibial Arteries in Patients with Chronic Limb Threatening Ischaemia is Associated with Fewer Major Re-interventions*
BibTeX
@misc{feredj2026autoantibodies,
title = {{Autoantibodies neutralizing type I interferons in patients with life-threatening COVID-19 pneumonia: a meta-analysis from 2020–2026}},
author = {Elsa Feredj and Qian Zhang and Paul Bastard and Jean-Laurent Casanova and Aurélie Cobat},
howpublished = {Medrxiv : the Preprint Server For Health Sciences},
year = {2026},
month = aug,
doi = {10.64898/2026.08.06.26359907},
url = {https://hal.science/hal-05863798v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Autoantibodies neutralizing type I interferons in patients with life-threatening COVID-19 pneumonia: a meta-analysis from 2020–2026
AU - Elsa Feredj
AU - Qian Zhang
AU - Paul Bastard
AU - Jean-Laurent Casanova
AU - Aurélie Cobat
PY - 2026
DA - 2026/08/10
PB - Medrxiv : the Preprint Server For Health Sciences
DO - 10.64898/2026.08.06.26359907
UR - https://hal.science/hal-05863798v1
AB - Autoantibodies neutralizing type I IFNs (AAN–IFN-I) have been found in significant proportions of cases of severe, critical, and fatal COVID-19 pneumonia. We performed a systematic review of 54 studies reporting auto-Abs against type I IFNs and a meta-analysis of 20 studies reporting auto- Abs neutralizing type I IFNs published between 2020 and 2026. The meta-analysis included data for 11,380 SARS-CoV-2-infected individuals from Europe, North America, South America, Asia, the Middle East, North Africa and international multicenter cohorts, including 7,814 with severe or critical disease (69%). The pooled prevalence of AAN–IFN-I was estimated at 7.9% (95% CI, 6.0–10.4). Disease severity was strongly associated with AAN–IFN-I prevalence (OR, 11.7; 95% CI, 7.6–17.9; P =5×10⁻²⁹). The pooled prevalence of AAN-IFN-I reached 11.4% (95% CI, 10.2– 12.7%) in patients with severe or critical COVID-19 and 15.3% (95% CI, 12.1–19.2%) in those who died. The prevalence of AAN–IFN-I increased with age in patients with severe, critical, or fatal COVID-19. AAN-IFN-I probably accounted for about 1.1 million of the 7.1 million deaths from COVID-19. AAN-IFN-I are strong, common, global determinants of life-threatening COVID-19 pneumonia.
ER -